Table 2.
Response to imatinib mesylate therapy (33 patients)
Response
.
No. response/no. evaluable (%)
.
CHR
11/11 (100)
Cytogenetic response
26/27 (96)
Complete
24/27 (89)
Major
19/21 (90)
Response
.
No. response/no. evaluable (%)
.
CHR
11/11 (100)
Cytogenetic response
26/27 (96)
Complete
24/27 (89)
Major
19/21 (90)
View Large
Close Modal
Close Modal
This Feature Is Available To Subscribers Only
Sign In
or
Create an Account
Close Modal
Close Modal